MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30109% above fair value
$3.85−0.10 (-2.53%)
Close on Nov 20, 2026Market cap $1.24BP/E –Yield –
MannKind gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
MannKind's gross profit for the twelve months ending Jun 30, 2026 was $353.29M, up 23.8% year over year. For fiscal 2025 it was $322.17M, up 20.2% from the year before. The highest annual figure on record is $322.17M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.17M | +20.2% |
| FY2024 | Dec 31, 2024 | $268.08M | +50.5% |
| FY2023 | Dec 31, 2023 | $178.10M | +112.6% |
| FY2022 | Dec 31, 2022 | $83.77M | +42.9% |
| FY2021 | Dec 31, 2021 | $58.61M | +17.1% |
| FY2020 | Dec 31, 2020 | $50.06M | +16.5% |
| FY2019 | Dec 31, 2019 | $42.96M | +407.4% |
| FY2018 | Dec 31, 2018 | $8.47M | – |
| FY2017 | Dec 31, 2017 | -$5.48M | -103.5% |
| FY2016 | Dec 31, 2016 | $157.64M | – |
| FY2015 | Dec 31, 2015 | -$64.75M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $94.97M | +32.0% |
| Q1 FY2026 | Mar 31, 2026 | $82.66M | +10.8% |
| Q4 FY2025 | Dec 31, 2025 | $98.03M | +36.2% |
| Q3 FY2025 | Sep 30, 2025 | $77.63M | +16.1% |
| Q2 FY2025 | Jun 30, 2025 | $71.92M | +7.7% |
| Q1 FY2025 | Mar 31, 2025 | $74.59M | +19.4% |
| Q4 FY2024 | Dec 31, 2024 | $71.97M | +37.5% |
| Q3 FY2024 | Sep 30, 2024 | $66.88M | +41.5% |
| Q2 FY2024 | Jun 30, 2024 | $66.78M | +53.9% |
| Q1 FY2024 | Mar 31, 2024 | $62.44M | +77.9% |
| Q4 FY2023 | Dec 31, 2023 | $52.36M | +63.7% |
| Q3 FY2023 | Sep 30, 2023 | $47.26M | +70.0% |
| Q2 FY2023 | Jun 30, 2023 | $43.39M | +203.9% |
| Q1 FY2023 | Mar 31, 2023 | $35.10M | +261.5% |
| Q4 FY2022 | Dec 31, 2022 | $31.98M | +289.0% |
| Q3 FY2022 | Sep 30, 2022 | $27.80M | +51.1% |
| Q2 FY2022 | Jun 30, 2022 | $14.28M | -24.3% |
| Q1 FY2022 | Mar 31, 2022 | $9.71M | -26.0% |
| Q4 FY2021 | Dec 31, 2021 | $8.22M | -44.4% |
| Q3 FY2021 | Sep 30, 2021 | $18.40M | +56.4% |
| Q2 FY2021 | Jun 30, 2021 | $18.87M | +65.0% |
| Q1 FY2021 | Mar 31, 2021 | $13.12M | +8.7% |
| Q4 FY2020 | Dec 31, 2020 | $14.79M | +30.2% |
| Q3 FY2020 | Sep 30, 2020 | $11.76M | +56.9% |
| Q2 FY2020 | Jun 30, 2020 | $11.44M | +7.1% |
| Q1 FY2020 | Mar 31, 2020 | $12.07M | -10.1% |
| Q4 FY2019 | Dec 31, 2019 | $11.36M | +2.9% |
| Q3 FY2019 | Sep 30, 2019 | $7.50M | – |
| Q2 FY2019 | Jun 30, 2019 | $10.68M | – |
| Q1 FY2019 | Mar 31, 2019 | $13.43M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$834.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.20M | – |
| Q1 FY2018 | Mar 31, 2018 | -$543.00K | -217.8% |
| Q4 FY2017 | Dec 31, 2017 | -$488.00K | -106.0% |
| Q3 FY2017 | Sep 30, 2017 | -$2.53M | -101.6% |
| Q2 FY2017 | Jun 30, 2017 | -$2.92M | – |
| Q1 FY2017 | Mar 31, 2017 | $461.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $8.20M | – |
| Q3 FY2016 | Sep 30, 2016 | $157.96M | – |
See a number that looks wrong?